Short answer
Anika Therapeutics, Inc. (ANIK) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $28M (down 28.2% year over year) with net income of −$2M.
Q3 2025 key financials · XBRL
- Revenue
- $28M
- −28.2% YoY · −1.4% QoQ
- Net income
- −$2M
- +92.2% YoY · +41.3% QoQ
- Operating margin
- -11.6%
- Gross margin
- 56.0%
- EPS (diluted)
- −$0.16
- +92.1% YoY · +42.9% QoQ
Source: XBRL data from the Anika Therapeutics, Inc. (ANIK) Q3 2025 10-Q on SEC EDGAR. USD.
Anika Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $27.8M, down 6% YoY from $29.6M, driven by lower OEM pricing
- Gross margin 56% vs 66% YoY; operating loss $3.2M vs $0.1M
- Best channel Commercial revenue $12.0M, up 22%; OEM revenue $15.8M, down 20%
- Cash $58.0M vs $55.6M at December 31, 2024; operating cash flow $6.6M vs $3.8M
- Near-term headwinds: lower J&J MedTech pricing, higher manufacturing costs, inventory reserves, and international mix
Risk Factors
- J&J MedTech divestiture announced October 2025, creating new revenue predictability risk for Monovisc and Orthovisc
- Hyalofast Phase III failed pre-specified co-primary endpoints, jeopardizing FDA approval and potential intangible-asset impairment
- FDA disruption from staffing reductions, leadership departures, policy changes, and October 1, 2025 government shutdown threatens review timelines
- Tariffs and retaliatory trade measures threaten imported manufacturing inputs and exported products
- J&J MedTech controls U.S. pricing, promotion, reimbursement strategy, and distribution for products generating a large revenue percentage
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anika Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.